What is Bharat Immunologicals & Biologicals Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Bharat Immunologicals & Biologicals Enterprise Value Chart
Competitive Comparison of Bharat Immunologicals & Biologicals's Enterprise Value
For the Biotechnology subindustry, Bharat Immunologicals & Biologicals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bharat Immunologicals & Biologicals's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bharat Immunologicals & Biologicals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Bharat Immunologicals & Biologicals's Enterprise Value falls into.
Bharat Immunologicals & Biologicals Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bharat Immunologicals & Biologicals (BOM:524663) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Bharat Immunologicals & Biologicals's EV-to-EBIT for today is
Bharat Immunologicals & Biologicals's current Enterprise Value is ₹2,018.90 Mil.
Bharat Immunologicals & Biologicals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-171.70 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Bharat Immunologicals & Biologicals's EV-to-EBITDA for today is:
Bharat Immunologicals & Biologicals's current Enterprise Value is ₹2,018.90 Mil.
Bharat Immunologicals & Biologicals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-169.75 Mil.
Bharat Immunologicals & Biologicals's current Enterprise Value is ₹2,018.90 Mil.
Bharat Immunologicals & Biologicals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹76.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bharat Immunologicals & Biologicals Enterprise Value Related Terms
Thank you for viewing the detailed overview of Bharat Immunologicals & Biologicals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Bharat Immunologicals & Biologicals (BOM:524663) Business Description
Bharat Immunologicals & Biologicals Corp Ltd is an India-based biotechnology company. It primarily manufactures Oral polio vaccines. In addition, the company also manufactures zinc tablets, diarrhea management kits, and Ready to Use Therapeutic Food (RUTF). It also manufactures nutraceuticals and biological products for the treatment of health deficiencies and disorders. The firm is organized into three segments: Oral Polio Vaccine, Zinc Tablets, and BIB VIT, BIBSANIT. The group principally operates in India and generates the majority of its revenue from sales of Oral polio vaccines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOM:524663 has been successfully added to your 